Agrochemical giant Bayer’s subsidiary Monsanto proposes class settlement for weedkiller cancer claims

Bayer has spent more than $10 billion settling thousands of cases linked to Roundup since it acquired its producer, the US agrochemical group Monsanto, in 2018.

German agrochemical giant Bayer said Tuesday its subsidiary Monsanto had proposed a class settlement of up to $7.25 billion to settle claims that the Roundup weedkiller causes blood cancer, potentially drawing a line under years of costly litigation.

Under the proposed agreement, Monsanto would make a series of declining annual payments for up to 21 years, Bayer said, adding that the deal still required court approval.

Bayer has spent more than $10 billion settling thousands of cases linked to Roundup since it acquired its producer, the US agrochemical group Monsanto, in 2018.

The International Agency for Research on Cancer considers glyphosate, one of Roundup's ingredients, a probable human carcinogen, but Bayer says scientific studies and regulatory approvals show the weedkiller is safe.

The US Supreme Court in January agreed to hear Bayer's appeal against an award of $1.25 million to a Missouri man who claimed Roundup was responsible for his blood cancer.

The company argues that it should be shielded from state lawsuits since the federal Environmental Protection Agency (EPA) approved the sale of Roundup to consumers and farmers without any warnings.

"The proposed class settlement agreement, together with the Supreme Court case, provides an essential path out of the litigation uncertainty," Bayer CEO Bill Anderson said in a statement.

"This litigation and the resulting cost underscore the need for guidance from the Supreme Court on clear regulation in American agriculture," he added.

Bayer shares surged after the announcement and were the best performer on Germany's bluechip DAX index, up 7.35 percent.